Processes for the preparation of uracil derivatives
US-10494347-B2 · Dec 3, 2019 · US
Processes for the preparation of uracil derivatives
US11459305B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11459305-B2 |
| Application number | US-202016739263-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 10, 2020 |
| Priority date | Nov 7, 2007 |
| Publication date | Oct 4, 2022 |
| Grant date | Oct 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A formulation comprising a spray-dried amorphous co-solution of a compound of formula 5-1 and an excipient or other carrier. 2. The formulation of claim 1 , wherein the excipient or other carrier is mannitol, polyvinyl pyrrolidone and/or hydroxypropylmethylcellulose. 3. A method for treating a condition selected from prostate cancer, breast cancer, endometriosis, uterine leiomyoma (fibroids), ovarian cancer, prostatic hyperplasia, assisted reproductive therapy, and precocious puberty in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the formulation of claim 1 . 4. The method of claim 3 , wherein the condition is endometriosis. 5. The method of claim 3 , wherein the condition is uterine leiomyoma (fibroids). 6. A formulation comprising an amorphous co-solution of a compound of formula 5-1 and an excipient or other carrier. 7. The formulation of claim 6 , wherein the excipient or other carrier is a polymer. 8. The formulation of claim 6 , wherein the excipient or other carrier is selected from mannitol, polyvinyl pyrrolidone and hydroxypropylmethylcellulose. 9. A method for treating a condition selected from prostate cancer, breast cancer, endometriosis, uterine leiomyoma (fibroids), ovarian cancer, prostatic hyperplasia, assisted reproductive therapy, and precocious puberty in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the formulation of claim 6 . 10. The method of claim 9 , wherein the condition is endometriosis. 11. The method of claim 9 , wherein the condition is uterine leiomyoma (fibroids).
Assignees
Inventors
Classifications
resulting in pure drug agglomerate optionally containing up to 5% of excipient · CPC title
with organic macromolecular compounds · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil · CPC title
- C07D239/54Primary
as doubly bound oxygen atoms or as unsubstituted hydroxy radicals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11459305B2 cover?
- The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
- Who is the assignee on this patent?
- Neurocrine Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D239/54. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).